Cervicovaginal fluid acetate, a marker for preterm birth in symptomatic pregnant women
Emmanuel Amabebe1, Steven Reynolds2, Victoria Stern1, Jennifer Parker3, Graham Stafford3, Martyn Paley2, and Dilly Anumba1

1Academic unit of Reproductive and Developmental Medicine, University of Sheffield, Sheffield, United Kingdom, 2Academic unit of Radiology, University of Sheffield, Sheffield, United Kingdom, 3School of Dentistry, University of Sheffield, Sheffield, United Kingdom

Synopsis

We characterized the metabolite profile of cervicovaginal fluid (CVF) of a cohort of pregnant women presenting with symptoms of preterm labor by both 1H Magnetic Resonance spectroscopy and spectrophotometric acetate enzyme assay. Acetate normalized integral (P=0.002) and spectrophotometry (P=0.006) were significantly higher in the women who delivered preterm compared to their term counterparts. Both methods were predictive of PTB <37 weeks (acetate integral: AUC=0.75, spectrophotometry: AUC=0.74). Elevated CVF acetate in women with symptoms of preterm labor appears predictive of preterm delivery. In these women, a clinical assay of acetate in CVF may prove of clinical utility for predicting PTB.

Introduction: Changes in the vaginal microecology of commensal and pathogenic organisms may influence the initiation of preterm birth (PTB),1 and can be detected in the cervicovaginal fluid (CVF) metabolite profile. We characterized and validated the metabolite profile of CVF of a cohort of pregnant women presenting with symptoms of preterm labor by both 1H Magnetic Resonance spectroscopy (MRS) and spectrophotometric assay, and determined their predictive capacity for PTB.

Methods: CVF was obtained by high-vaginal swabs from 86 pregnant women presenting with symptoms of preterm labor (i.e. regular uterine contractions and < 3 cm dilated cervix), but with intact membranes and no evidence of genital infection, between 24 and 36 weeks (wks) gestation. Vaginal secretions were dissolved in 600 µl sterile phosphate buffered saline and a 400 µl MR sample containing 20 µl D2O was scanned with a 9.4T Bruker Avance III MR spectrometer (Bruker BioSpin GmbH, Karlsruhe, Germany), with 5mm BBO probe using a Watergate water suppression pulse sequence (NS = 256, D1 = 5s, AQ = 1s, SW = 20.6 ppm, TD = 16446). Acetate and other metabolites were identified in the MR spectrum, integrated for peak area and normalized to the total spectrum integral (excluding water signal). Acetate concentrations (AceConc) were also determined from a randomly selected subset of the same samples (n = 57), by spectrophotometric absorption of NADH using acetic acid assay kit (K-ACETGK 08/14, Megazyme, IE).

Results: Acetate normalized integral (P = 0.002) and AceConc (P = 0.006) were significantly higher in the women who delivered preterm compared to their term counterparts (Fig. 1). The MR derived acetate integrals were strongly correlated with the AceConc estimated from the spectrophotometric technique (r = 0.69; P < 0.0001) (Fig. 2). Both methods were predictive of PTB < 37 wks (acetate integral: AUC = 0.75, LR+ = 4.0, LR- = 0.3; AceConc: AUC = 0.74, LR+ = 2.5, LR- = 0.4) (Fig. 3). Additionally, acetate 1H integrals and AceConc were predictive of delivery within 2 weeks of the index assessment (acetate integral: AUC = 0.77, LR+ = 2.0, LR- = 0.5; AceConc: AUC = 0.68, LR+ = 3.1, LR- = 0.3) with an optimal cut-off of > 0.54 g/l (Fig. 4). Normalized integrals of succinate, formate, lactate, glucose, glutamine/glutamate, alanine and branched chain amino acids did not differ between term- and preterm-delivered cohorts.

Conclusion: Elevated CVF acetate in women with symptoms of preterm labor appears predictive of preterm delivery, as well as delivery within 2 weeks of presentation. In these women, a clinical assay of acetate in CVF may prove of clinical utility for predicting PTB.

Acknowledgements

This study was supported by a grant from the Medical Research Council, UK; and a PhD studentship from the Niger Delta Development Commission and Bayelsa State Scholarship Board of Nigeria.

References

1. Witkin SS. BJOG 2015; 122(2):213-8.

Figures

Fig. 1. Comparison of cervicovaginal fluid acetate of symptomatic pregnant women in relation to delivery outcome (a) Acetate normalized integral, (b) Acetate concentration

Fig. 2. Cervicovaginal fluid acetate of symptomatic pregnant women estimated by 1H MRS and Spectrophotometry

Fig. 3. Predictive capacity of cervicovaginal fluid acetate for preterm birth (<37 weeks) in symptomatic pregnant women (a) Acetate normalized integral, (b) Acetate concentration

Fig. 4. Predictive capacity of cervicovaginal fluid acetate for delivery within two weeks of presentation in symptomatic pregnant women (a) Acetate normalized integral, (b) Acetate concentration



Proc. Intl. Soc. Mag. Reson. Med. 24 (2016)
2414